[go: up one dir, main page]

DK1042355T3 - 11beta-halo-7alpha-substituted estratrienes, process for the preparation of pharmaceutical compositions containing these 11beta-halo-7alpha-substituted estratrienes, and their use in the manufacture of pharmaceuticals - Google Patents

11beta-halo-7alpha-substituted estratrienes, process for the preparation of pharmaceutical compositions containing these 11beta-halo-7alpha-substituted estratrienes, and their use in the manufacture of pharmaceuticals

Info

Publication number
DK1042355T3
DK1042355T3 DK98966410T DK98966410T DK1042355T3 DK 1042355 T3 DK1042355 T3 DK 1042355T3 DK 98966410 T DK98966410 T DK 98966410T DK 98966410 T DK98966410 T DK 98966410T DK 1042355 T3 DK1042355 T3 DK 1042355T3
Authority
DK
Denmark
Prior art keywords
7alpha
11beta
halo
substituted estratrienes
pharmaceuticals
Prior art date
Application number
DK98966410T
Other languages
Danish (da)
Inventor
Rolf Bohlmann
Nikolaus Heinrich
Helmut Hofmeister
Jorg Kroll
Hermann Kuenzer
Gerhard Sauer
Ludwig Zorn
Karl-Heinrich Fritzemeier
Monika Lessl
Rosemarie Lichtner
Yukishige Nishino
Karsten Parczyk
Martin Schneider
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1997158390 external-priority patent/DE19758390A1/en
Priority claimed from DE1998106357 external-priority patent/DE19806357A1/en
Application filed by Schering Ag filed Critical Schering Ag
Application granted granted Critical
Publication of DK1042355T3 publication Critical patent/DK1042355T3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32Antioestrogens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J31/00Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0072Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J43/00Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK98966410T 1997-12-23 1998-12-23 11beta-halo-7alpha-substituted estratrienes, process for the preparation of pharmaceutical compositions containing these 11beta-halo-7alpha-substituted estratrienes, and their use in the manufacture of pharmaceuticals DK1042355T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE1997158390 DE19758390A1 (en) 1997-12-23 1997-12-23 New 11beta-halo-7alpha-substituted-estratriene derivatives are useful for treatment e.g. various cancers, anovulatolial infertility, male hair loss, osteoporosis, and contraceptives
DE1998106357 DE19806357A1 (en) 1998-02-10 1998-02-10 New 11 beta-halo-7 alpha-substituted estratrienes useful for treating e.g. estrogen-dependent disease such as breast cancer
PCT/EP1998/008470 WO1999033855A1 (en) 1997-12-23 1998-12-23 11β-HALOGEN-7α-SUBSTITUTED ESTRATRIENES, METHOD FOR PRODUCING PHARMACEUTICAL PREPARATIONS CONTAINING SAID 11β-HALOGEN-7α-SUBSTITUTED ESTRATRIENES AND USE OF THE SAME FOR PRODUCING MEDICAMENTS

Publications (1)

Publication Number Publication Date
DK1042355T3 true DK1042355T3 (en) 2003-04-22

Family

ID=26042916

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98966410T DK1042355T3 (en) 1997-12-23 1998-12-23 11beta-halo-7alpha-substituted estratrienes, process for the preparation of pharmaceutical compositions containing these 11beta-halo-7alpha-substituted estratrienes, and their use in the manufacture of pharmaceuticals

Country Status (27)

Country Link
US (1) US6780855B2 (en)
EP (1) EP1042355B1 (en)
JP (1) JP2001527088A (en)
KR (1) KR20010024806A (en)
CN (1) CN1131235C (en)
AR (1) AR015500A1 (en)
AT (1) ATE232543T1 (en)
AU (1) AU750801B2 (en)
BG (1) BG104553A (en)
BR (1) BR9814416A (en)
CA (1) CA2316444A1 (en)
DE (1) DE59807213D1 (en)
DK (1) DK1042355T3 (en)
EA (1) EA002623B1 (en)
EE (1) EE200000380A (en)
ES (1) ES2191371T3 (en)
HU (1) HUP0100568A3 (en)
ID (1) ID26207A (en)
IL (1) IL136938A0 (en)
IS (1) IS5526A (en)
NO (1) NO20003286L (en)
NZ (1) NZ505348A (en)
PE (1) PE20000129A1 (en)
PL (1) PL341299A1 (en)
SK (1) SK9442000A3 (en)
TR (1) TR200001973T2 (en)
WO (1) WO1999033855A1 (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03002953A (en) * 2000-10-18 2003-08-07 Schering Ag Inhibition of the growth factor dependency of tumor cells.
AU2006202187B2 (en) * 2001-11-27 2008-11-06 Bayer Schering Pharma Aktiengesellschaft 17alpah-alkyl-17beta-oxy-estratrienes and intermediate products for their production, uses thereof and pharmaceutical preparations
DE10159217A1 (en) * 2001-11-27 2003-06-05 Schering Ag 17alpha-alkyl-17ß-oxy-estratrienes and intermediates for their preparation, use of 17alpha-alkyl-17ß-oxy-estratriene for the preparation of medicaments and pharmaceutical preparations
US20040242551A1 (en) * 2003-05-28 2004-12-02 Schering Ag Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases
AU2003267773A1 (en) * 2003-10-14 2005-04-27 Council Of Scientific And Industrial Research (3r, 4r)-trans-3,4-diarylchroman derivatives with estrogenic activity
EP1771462B1 (en) * 2004-07-27 2010-09-29 Sicor Inc. A process for the preparation of 7-alpha-alkylated 19-norsteroids
WO2007060839A1 (en) 2005-11-22 2007-05-31 Sumitomo Chemical Company, Limited Organic sulfur compounds and use thereof as arthropodicides
DE102007023614A1 (en) 2007-05-21 2008-11-27 Bayer Schering Pharma Aktiengesellschaft New amide compounds used for treatment of gynecological diseases e.g. endometriosis, for female fertility control and female hormone replacement therapy, has general formula
DE102007049630A1 (en) 2007-10-11 2009-10-29 Bayer Schering Pharma Aktiengesellschaft New amide compounds used for therapy and/or prophylaxis of gynecological diseases e.g. endometriosis, for female fertility control and female hormone replacement therapy
TW200904329A (en) 2007-05-18 2009-02-01 Sumitomo Chemical Co Organic sulfur compound and its use for controlling harmful arthropod
JP2009001551A (en) 2007-05-18 2009-01-08 Sumitomo Chemical Co Ltd Organic sulfur compounds and their use for controlling harmful arthropods
JP5298631B2 (en) 2007-05-18 2013-09-25 住友化学株式会社 Organic sulfur compounds and their use for controlling harmful arthropods
DE102007032800A1 (en) 2007-07-10 2009-01-15 Bayer Schering Pharma Aktiengesellschaft Nonsteroidal progesterone receptor modulators
EP2033948A1 (en) * 2007-08-30 2009-03-11 Bayer Schering Pharma Aktiengesellschaft Process for preparing Estrogen-antagonistic 11beta-Fluoro-17alpha-alkylestra-1,3,5 (10)-triene-3, 17-diols having a 7alpha-(xi-Alkylamino-omega-perfluoroalkyl)alkyl side chain and alpha-Alkyl(amino)-omega-perfluoro(alkyl)alkanes and processes for their preparation
CN102940619A (en) 2007-10-16 2013-02-27 利普生物药剂公司 Trans-clomiphene for metabolic syndrome
EP2053055A1 (en) * 2007-10-24 2009-04-29 Bayer Schering Pharma Aktiengesellschaft 11.beta.-fluoro-3-acetoxyestra-3,5-diene-17-one and method for its manufacture
DE102007058747A1 (en) 2007-12-05 2009-06-10 Bayer Schering Pharma Aktiengesellschaft Nonsteroidal progesterone receptor modulators
EP2070942A1 (en) 2007-12-13 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Method for aromatising 19-nor-androst-4-en-3-ones to estra-1,3,5(10)-trienes
EP2070941A1 (en) 2007-12-14 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Stereoselective synthesis of selective estrogen receptor down-regulators
EP2070909A1 (en) 2007-12-15 2009-06-17 Bayer Schering Pharma AG Non-steroidal progesterone receptor modulators
EP2258375A1 (en) 2009-06-04 2010-12-08 Bayer Schering Pharma Aktiengesellschaft 17B-alkyl-17alpha-oxy-estratrienes
DE102009034366A1 (en) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluoroethyl-estra-4,9 (10) -diene-11-methyleneoxyalkylene aryl derivatives, process for their preparation and their use for the treatment of diseases
DE102009034362A1 (en) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluoroethyl-estra-4,9 (10) -diene-11-aryl derivatives, process for their preparation and their use for the treatment of diseases
DE102009034367A1 (en) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluoroethyl-estra-4,9 (10) -diene-11-benzylidene derivatives, process for their preparation and their use for the treatment of diseases
DE102009034368A1 (en) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluoroethyl-estra-4,9 (10) -diene-11-acyloxyalkylenephenyl derivatives, process for their preparation and their use for the treatment of diseases
DE102009034526A1 (en) 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluoroethyl-estra-4,9 (10) -diene-11-ethynylphenyl derivatives, process for their preparation and their use for the treatment of diseases
DE102009034525A1 (en) 2009-07-21 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluoroethyl-estra-4,9 (10) -diene-11-aryl derivatives, process for their preparation and their use for the treatment of diseases
DE102010007722A1 (en) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesterone receptor antagonist
DE102010007719A1 (en) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesterone receptor antagonist
DE102010030538A1 (en) 2010-06-25 2011-12-29 Bayer Schering Pharma Aktiengesellschaft 6,7-Dihydro-5H-benzo [7] annulene derivatives, process for their preparation, pharmaceutical preparations containing them and their use for the preparation of medicaments
DE102011004899A1 (en) 2011-03-01 2012-09-06 Bayer Pharma Aktiengesellschaft New 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl-derivatives are progesterone receptor antagonists useful to treat and prevent e.g. uterine fibroids, endometriosis, heavy menstrual bleeding and meningioma
DE102011087987A1 (en) 2011-12-08 2013-06-13 Bayer Intellectual Property Gmbh 6,7-Dihydro-5H-benzo [7] annulene derivatives, process for their preparation, pharmaceutical preparations containing them and their use for the preparation of medicaments
MX2014009322A (en) 2012-02-29 2014-11-10 Repros Therapeutics Inc Combination therapy for treating androgen deficiency.
US20160296534A1 (en) 2013-04-11 2016-10-13 Bayer Pharma Aktiengesellschaft Progesterone receptor antagonist dosage form
WO2014169462A1 (en) * 2013-04-18 2014-10-23 西安力邦医药科技有限责任公司 Ester derivative of 7-alpha-[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17beta-diol having antitumour activity and preparation method thereof
CN104387435B (en) * 2014-12-10 2017-05-10 天津孚音生物科技发展有限公司 Compound and preparation method and application thereof
CN106146599A (en) * 2015-04-07 2016-11-23 江苏希迪制药有限公司 A kind of recovery is because of the method for sulfoxide configuration ratio underproof fulvestrant or derivatives thereof
JP7048505B2 (en) 2015-11-10 2022-04-05 パラクリン セラピューティクス エービー Treatment of ER-negative breast cancer with PDGF-CC inhibitors and antiestrogens
CN112778089B (en) * 2021-01-04 2023-09-05 万知科技股份有限公司 New synthetic method of 4, 4-trifluoro-1-butanol and homologs thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3076829A (en) * 1961-09-15 1963-02-05 Schering Corp Novel 9, 11-disubstituted estratriene derivatives
GB8327256D0 (en) * 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
HU208150B (en) * 1988-10-31 1993-08-30 Endorecherche Inc Process for producing new estrogen derivatives having steroid hormone inhibitor activity and pharmaceutical compositions comprising such derivatives
DE19635525A1 (en) * 1996-08-20 1998-02-26 Schering Ag New 7-alpha-(xi-aminoalkyl)- oestratriene derivatives
US5866560A (en) * 1996-08-20 1999-02-02 Schering Ag 7α-(ξ-aminoalkyl)-estratrienes, process for their production, pharmaceutical preparations which contain these 7α-(ξ-aminoalkyl)-estratrienes as well as their use for the production of pharmaceutical agents

Also Published As

Publication number Publication date
KR20010024806A (en) 2001-03-26
EA002623B1 (en) 2002-06-27
AU750801B2 (en) 2002-07-25
EP1042355B1 (en) 2003-02-12
WO1999033855A1 (en) 1999-07-08
CN1131235C (en) 2003-12-17
DE59807213D1 (en) 2003-03-20
PE20000129A1 (en) 2000-03-11
HUP0100568A3 (en) 2002-01-28
IL136938A0 (en) 2001-06-14
ATE232543T1 (en) 2003-02-15
CA2316444A1 (en) 1999-07-08
NZ505348A (en) 2002-10-25
EE200000380A (en) 2001-12-17
NO20003286L (en) 2000-08-23
ID26207A (en) 2000-12-07
HUP0100568A2 (en) 2001-08-28
ES2191371T3 (en) 2003-09-01
SK9442000A3 (en) 2001-04-09
US20030069434A1 (en) 2003-04-10
IS5526A (en) 2000-06-09
EA200000711A1 (en) 2001-02-26
PL341299A1 (en) 2001-04-09
US6780855B2 (en) 2004-08-24
AR015500A1 (en) 2001-05-02
BG104553A (en) 2001-02-28
AU2276399A (en) 1999-07-19
CN1286693A (en) 2001-03-07
EP1042355A1 (en) 2000-10-11
JP2001527088A (en) 2001-12-25
TR200001973T2 (en) 2001-01-22
BR9814416A (en) 2000-10-10
NO20003286D0 (en) 2000-06-22

Similar Documents

Publication Publication Date Title
DK1042355T3 (en) 11beta-halo-7alpha-substituted estratrienes, process for the preparation of pharmaceutical compositions containing these 11beta-halo-7alpha-substituted estratrienes, and their use in the manufacture of pharmaceuticals
DK0920441T3 (en) 7alpha (epsilon-aminoalkyl) -estratrienes, processes for their preparation, pharmaceutical compositions containing these 7-alpha (epsilon-aminoalkyl) -estratrienes, and their use in the manufacture of pharmaceuticals
DK1173441T3 (en) 6-alkenyl, 6-alkynyl and 6-epoxy-epothilone derivatives, processes for their preparation and their use in pharmaceutical compositions
DK1098874T3 (en) Benzocycloheptenes, Methods of Preparation, Pharmaceutical Preparations Containing Them, and Their Use in the Preparation of Drugs
DK0807111T3 (en) Substituted heterocyclic compounds, processes for their preparation and pharmaceutical compositions containing them
DK1275387T3 (en) Process for the preparation of high-bioavailability phenofibrate pharmaceutical compositions
DK1066049T3 (en) Pharmaceutical compositions intended for the sustained release of peptides and methods for their preparation
NO20003254L (en) Anti-estrogenic steroids and pharmaceutical compositions containing the same, and their use
PT981375E (en) PHARMACEUTICAL COMPOSITIONS CONTAINING PLASMA PROTEINS
HUP0001539A3 (en) 2-(1-iminoethylamino)ethyl-homocysteine, process for its preparation and pharmaceutical compositions containing the same
HUP0001508A3 (en) 4-arylmethylene-2-imino-2,3-dihydrothiazole derivatives, their use, process for the preparation thereof and pharmaceutical compositions containing them
DK0991654T3 (en) New derivatives of 2- (iminomethyl) aminophenyl, their preparation, their use in drugs and pharmaceutical compositions containing the same
HUP0000851A3 (en) Novel pyrimidine derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
KR100547921B1 (en) Sulfonamide-substituted chromamann, methods for the preparation thereof and pharmaceutical compositions comprising the same
NO20030296L (en) Heparin-derived polysaccharide mixtures, their preparation and pharmaceutical compositions containing the compositions
DK1140824T3 (en) Process for the preparation of 3-alkanoyl and 3-alkylindoles
DK1117661T3 (en) Propanolamine derivatives substituted with heterocyclic groups, process for their preparation, pharmaceutical preparations containing these compounds and their use
HUP0001093A3 (en) Oxazolidines as 5-ht2a-antagonists, pharmaceutical compositions containing the same and process for their preparation
HRP20000479B8 (en) NEW PENTASACCHARIDES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL MIXTURES CONTAINING THEM
DK1015433T3 (en) Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-ols, processes for their preparation and their use as drugs
DK1118610T3 (en) Benzenesulfonamide derivatives, process for their preparation and pharmaceutical compositions containing the derivatives
EE03996B1 (en) Pharmaceutical compositions, process for their preparation and use
DK1171444T3 (en) Pyridothienodiazepines, process for their preparation and pharmaceutical compositions containing them
NO960529D0 (en) Substituted benzenesulfonylureas and thioureas, processes for their preparation and their use in the preparation of pharmaceutical compositions and pharmaceutical compositions containing the compounds
EE04260B1 (en) Pharmaceutical composition, process for its preparation and use